Comprehensive Multi‐Omics Analysis Reveals NPC2 and ITGAV Genes as Potential Prognostic Biomarkers in Gastrointestinal Cancers
2024

NPC2 and ITGAV Genes as Potential Biomarkers in Gastrointestinal Cancers

Sample size: 1659 publication 10 minutes Evidence: moderate

Author Information

Author(s): Moein Piroozkhah, Mohammadreza Zabihi, Pooya Jalali, Zahra Salehi

Primary Institution: Shahid Beheshti University of Medical Sciences

Hypothesis

Can NPC2 and ITGAV serve as reliable prognostic biomarkers for gastrointestinal cancers?

Conclusion

NPC2 and ITGAV may be used as potential biomarkers to determine the prognosis of various gastrointestinal cancers and are related to immune infiltration.

Supporting Evidence

  • High expression levels of NPC2 and ITGAV were linked to poorer prognosis in liver and stomach cancers.
  • NPC2 and ITGAV were found to be significantly associated with tumor stage in liver and pancreatic cancers.
  • Alterations in NPC2 and ITGAV were observed in a small percentage of patients, indicating their potential as biomarkers.

Takeaway

Scientists found two genes, NPC2 and ITGAV, that can help doctors predict how bad gastrointestinal cancers might be for patients.

Methodology

The study used various bioinformatics databases to analyze gene expression, methylation, and genetic alterations of NPC2 and ITGAV in gastrointestinal cancers.

Potential Biases

Potential bias due to the retrospective nature of the data and small sample sizes for some cancer types.

Limitations

The study relies on retrospective data from online databases, which may skew towards late-stage patients with high-quality specimens.

Participant Demographics

Patients with gastrointestinal cancers including COAD, LIHC, PAAD, and STAD.

Statistical Information

P-Value

0.00575

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1002/cnr2.70087

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication